

Table 1 Baseline characteristics of the sample.

Characteristic	All patients (N = 32)
Age, mean \pm SD, yr	64 \pm 10
Male, n (%)	24 (75)
Body surface area, mean \pm SD, m ²	1.87 \pm 0.2
Chronic kidney disease, n (%)	10 (31)
Ischemic cardiomyopathy, n (%)	12 (37)
NYHA functional class at enrollment, n (%)	
Class II	17 (53)
Class III	15 (47)
Medical treatment, n (%)	
ACE inhibitor or ARB	29 (91)
Beta blockers	26 (81)
Aldosterone antagonist	23 (72)
ECG variables	
QRS morphology, n (%)	
LBBB	31 (97)
Nonspecific intraventricular conduction delay	1 (3)
QRS duration, mean \pm SD, ms	177 \pm 17
PR duration, mean \pm SD, ms	192 \pm 35
Echocardiographic variables	
LVEF, mean \pm SD, %	29 \pm 6
LVESV, mean \pm SD, mL	103 \pm 40

LVEDV, mean \pm SD, mL	192 \pm 62
--	--------------------------------

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ECG, electrocardiography; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MPP, multipoint pacing; NYHA, New York Heart Association; SD, standard deviation.